NATHBIOGEN

What Nath Bio-Genes (India) promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q4 FY26

what the last two calls moved 8 tracked 1 delivered 3 missed 4 open
  • Revenue Growth delivered said Q4 FY25 Promised: 15% revenue growth for this year (FY26) Q4 FY26: Achieved. Full year FY26 revenue grew 19% YoY to INR 431.6 crores, exceeding the 15% target.
  • EBITDA/PBT Margin missed said Q4 FY25 Promised: Increase about 2 to 3 basis points Q4 FY26: Missed. Gross margin compressed to 56% from 63% in FY25. EBITDA margin for FY26 was 12%, and PAT margin fell to 9%. Management attributed the drop to higher finance and marketing costs.
  • Total Sales on track said Q4 FY25 Promised: Cross INR 500 crores in a year or 2 Q4 FY26: FY26 sales were INR 431.6 crores, crossing the INR 400 crore prerequisite mentioned in Q2. Management reiterated the goal, stating they 'hope to cross INR 500 crores of top line soon.'

The rest of the ledger

Above is what the last two calls moved. Pro opens all 8 tracked commitments for Nath Bio-Genes (India) — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens